If oncology drug development is considered race to the market, the fever around combinations with immune checkpoint inhibitors is turning it into a sprint. The pace at which clinical development is rapidly evolving has rendered the clinical trial landscape-especially for immune checkpoint inhibitors-an important headache that drug developers need addressing. Since Keytruda's approval in 2014 [...]The post ASCO 2018 Highlights Difficulties Developing Combinations with ICIs appeared first on DRG.
